Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression
The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After 1 week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some users react differently to the same antidepressant [19] while different antidepressants produce different effects [20].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [20]
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“(Hamilton, 1960).”
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923 · cited 1×
“To determine if one drug acts faster than the other and/ or placebo in reducing the overall severity or specific symptomatic behaviors during this 2-week treatment period, the linear mixed model (Laird and Ware, 1982) was used to model the longitudinal change in each construct.”
MethodKupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 2×
“…approach (Katz et al, 1984), doctor ratings included the Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and…”
MethodThe Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · cited 1×
“…Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and Itil, 1974); nurse ratings: the Affective Disorder Rating Scale…”
BackgroundAn inventory for assessing different kinds of hostility.
Buss, A. H., & Durkee, A. (1957) · Journal of Consulting Psychology · doi:10.1037/h0046900 · Cited by 2,575 · cited 2×
“…(Murphy et al, 1980), NIMH Mood Scale (Raskin et al, 1969), Global Ward Behavior Scale (Raskin et al, 1969); patient self-reports included the Symptoms Checklist (SCL-90; Derogatis et al, 1974); NIMH Mood Scale (Raskin et al, 1969); and the Buss–Durkee Hostility Inventory (Buss and Durkee, 1957).”
MethodWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“This later behavioral effect of paroxetine may not be due to serotonin exclusively, but to sequential or direct interactions between serotonin and noradrenergic or even dopaminergic systems (Willner, 1997; Bonhomme and Esposito, 1998; Bourin et al, 2001).”
BackgroundLinnoila, M., Virkkunen, M., Scheinin, M., Nuutila, A., Rimon, R., & Goodwin, F. K. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90344-2 · Cited by 1,308 · cited 1×
“More specifically at the behavioral level, it has been associated with the regulation of impulsivity (Soubrié, 1986), aggression (Linnoila et al, 1983), and anxiety (Briley and Chopin, 1991).”
BackgroundCoccaro, E. F. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810070013002 · Cited by 1,086
Reconciling the role of central serotonin neurons in human and animal behavior
Soubrié, P. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00022871 · Cited by 996 · cited 4×
“From a behavioral perspective, the activation of serotonergic neurons has been hypothesized to produce behavioral inhibition (Soubrié, 1986; Spoont, 1992; Handley, 1995), that is, serotonin may promote response suppression, inhibition, passivity, and waiting.”
BackgroundInfluentialThe Hopkins Symptom Checklist (HSCL)
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395070 · Cited by 894 · cited 1×
“…(Murphy et al, 1980), NIMH Mood Scale (Raskin et al, 1969), Global Ward Behavior Scale (Raskin et al, 1969); patient self-reports included the Symptoms Checklist (SCL-90; Derogatis et al, 1974); NIMH Mood Scale (Raskin et al, 1969); and the Buss–Durkee Hostility Inventory (Buss and Durkee, 1957).”
MethodGender Differences in Treatment Response to Sertraline Versus Imipramine in Chronic Depression
Kornstein, S. G., Schatzberg, A. F., Thase, M. E., Yonkers, K. A., McCullough, J. P., Keitner, G. I., Gelenberg, A. J., Davis, S. M., Harrison, W. M., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1445 · Cited by 702
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655
Carlsson, A., Corrodi, H., Fuxe, K., & Hökfelt, T. (1969) · European Journal of Pharmacology · doi:10.1016/0014-2999(69)90113-7 · Cited by 643 · cited 1×
“Although its effect in reducing motor retardation has been noted frequently since the early descriptions by Kielholz and Poldinger (1968) and Carlsson et al (1969), there has been little hard evidence until now that this is a specific clinical action of DMI, that is, an effect greater than that…”
BackgroundTHE TREATMENT OF DEPRESSIVE STATES WITH G 22355 (IMIPRAMINE HYDROCHLORIDE)
KUHN, R. (1958) · American Journal of Psychiatry · doi:10.1176/ajp.115.5.459 · Cited by 615 · cited 2×
“Central to the study and to our analysis, however, is the controversy over whether ADs take several weeks to initiate clinical action (eg Quitkin et al, 1984) or whether the behavioral effects begin to act sooner, within the first week, as originally observed (Kuhn, 1958; Kielholz and Poldinger, 1968; Angst, 1970), an…”
BackgroundBerridge, C., & Foote, S. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-10-03135.1991 · Cited by 434 · cited 1×
“Brain noradrenergic activity is closely associated with behavioral and physiological indices of arousal, such as locomotion, eye movements, EEG activity, heart rate, and overt behavioral activity (Rasmussen et al, 1986; Berridge and Foote, 1991; Page et al, 1993; Rosario and Abercrombie, 1999).”
BackgroundBourin, M., Chue, P., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 408 · cited 1×
“This later behavioral effect of paroxetine may not be due to serotonin exclusively, but to sequential or direct interactions between serotonin and noradrenergic or even dopaminergic systems (Willner, 1997; Bonhomme and Esposito, 1998; Bourin et al, 2001).”
BackgroundSpoont, M. R. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.2.330 · Cited by 408 · cited 1×
“From a behavioral perspective, the activation of serotonergic neurons has been hypothesized to produce behavioral inhibition (Soubrié, 1986; Spoont, 1992; Handley, 1995), that is, serotonin may promote response suppression, inhibition, passivity, and waiting.”
BackgroundRASKIN, A., SCHULTERBRANDT, J., REATIG, N., & McKEON, J. J. (1969) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196901000-00010 · Cited by 373 · cited 5×
“The patient completes the full NIMH Mood Scale and SCL-90 and the psychomotor performance tests at baseline and at 42 days (outcome).”
MethodInfluentialSingle unit activity of locus coeruleus neurons in the freely moving cat
Rasmussen, K., Morilak, D. A., & Jacobs, B. L. (1986) · Brain Research · doi:10.1016/0006-8993(86)90370-7 · Cited by 324 · cited 1×
“Brain noradrenergic activity is closely associated with behavioral and physiological indices of arousal, such as locomotion, eye movements, EEG activity, heart rate, and overt behavioral activity (Rasmussen et al, 1986; Berridge and Foote, 1991; Page et al, 1993; Rosario and Abercrombie, 1999).”
BackgroundPredictors of Drug Response in Depression
Joyce, P. R. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010091014 · Cited by 280 · cited 1×
“There has been great difficulty in prior studies trying to identify predictors of AD response based on pretreatment patient characteristics (Joyce and Paykel, 1989).”
ResultChaouloff, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00008-1 · Cited by 253 · cited 1×
“Some consider serotonin to function mainly in a tonic steady-state mode of activity also related primarily to behavioral arousal (Rueter and Jacobs, 1996), although this relationship can be Neuropsychopharmacology modified (Chaouloff et al, 1999).”
BackgroundRole of norepinephrine in depression.
Delgado, P. L., & Moreno, F. A. (2000) · PubMed · Cited by 251
Pollack, M. H., Zaninelli, R., Goddard, A., McCafferty, J. P., Bellew, K. M., Burnham, D. B., & Iyengar, M. K. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0508 · Cited by 246 · cited 1×
“The pattern is further supported by paroxetine’s use as an ‘anxiolytic’, now FDA approved for the treatment of a range of anxiety disorders (Dunbar and Fuell, 1992; Lydiard and Bobes, 2000; Pollack et al, 2001).”
Background5-Hydroxytryptamine pathways in anxiety and its treatment
Handley, S. L. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00004-z · Cited by 243 · cited 2×
“From a behavioral perspective, the activation of serotonergic neurons has been hypothesized to produce behavioral inhibition (Soubrié, 1986; Spoont, 1992; Handley, 1995), that is, serotonin may promote response suppression, inhibition, passivity, and waiting.”
BackgroundThe Long-Term Outcome of Depressive Illness
Kiloh, L. G., Andrews, G., & Neilson, M. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.153.6.752 · Cited by 234 · cited 1×
“…MSC 7764, San Antonio, TX, USA, Tel: +1-210-567-4205, E-mail: frazer@uthscsa.edu Neuropsychopharmacology (2004) 29, 566–579 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org risk of suicide from prolonged depressive symptoms (Kiloh et al, 1988).”
BackgroundInfluentialKirby, L. G., Allen, A. R., & Lucki, I. (1995) · Brain Research · doi:10.1016/0006-8993(95)00349-u · Cited by 228 · cited 1×
“Others, though, consider that even if there is some constant tonic level of serotonergic activity, there can still be local modulation of serotonin release that may be both brain region and stimulus specific (Kirby et al, 1995, 1997).”
BackgroundIdentification of True Drug Response to Antidepressants: Use of Pattern Analysis
Quitkin, F. M. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790190056007 · Cited by 221 · cited 2×
“Central to the study and to our analysis, however, is the controversy over whether ADs take several weeks to initiate clinical action (eg Quitkin et al, 1984) or whether the behavioral effects begin to act sooner, within the first week, as originally observed (Kuhn, 1958; Kielholz and Poldinger,…”
BackgroundResultKirby, L. G., Chou-Green, J. M., Davis, K., & Lucki, I. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00287-4 · Cited by 201
Use of Pattern Analysis to Identify True Drug Response: A Replication
Quitkin, F. M. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800150071009 · Cited by 191
Time course of improvement under antidepressant treatment: A survival-analytical approach
Stassen, H. H., Delini-Stula, A., & Angst, J. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90264-m · Cited by 191
Rueter, L. E., & Jacobs, B. L. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00809-8 · Cited by 183 · cited 2×
“Some consider serotonin to function mainly in a tonic steady-state mode of activity also related primarily to behavioral arousal (Rueter and Jacobs, 1996), although this relationship can be Neuropsychopharmacology modified (Chaouloff et al, 1999).”
BackgroundAston-Jones, G., Akaoka, H., Charlety, P., & Chouvet, G. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-03-00760.1991 · Cited by 180 · cited 1×
“Tonic noradrenergic activity is closely related to the overall state of behavioral arousal, which may be conceptualized as the degree to which an organism is ‘engaged’ with or responsive to its external environment (Aston-Jones et al, 1991; Jacobs et al, 1991).”
BackgroundSzegedi, A., Müller, M. J., Anghelescu, I., Klawe, C., Kohnen, R., & Benkert, O. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0410 · Cited by 174
The timing, specificity and clinical prediction of tricyclic drug effects in depression
Katz, M. M., Koslow, S. H., Maas, J. W., Frazer, A., Bowden, C. L., Casper, R., Croughan, J., Kocsis, J., & Redmond, E. (1987) · Psychological Medicine · doi:10.1017/s0033291700024831 · Cited by 167 · cited 5×
“We previously reported that the onset of improvement in several symptom domains in hospitalized patients with major depressive disorder who were treated with tricyclic antidepressants (TCAs) occurred within the first 10 days of treatment (Katz et al, 1987).”
BackgroundMethodInfluentialSelf-citationTreatment strategies for chronic and refractory obsessive-compulsive disorder.
Rasmussen, S. A., & Eisen, J. L. (1997) · PubMed · Cited by 138
Gelenberg, A. J., & Chesen, C. L. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1002 · Cited by 127 · cited 2×
“…was at variance with the then current view that despite the almost immediate impact of ADs on the functioning of central monoamine transmitter systems, the clinical actions of the drugs ‘lag’, that is, were not thought to occur until after 2–3 weeks of treatment (see Gelenberg and Chesen, 2000).”
BackgroundPage, M. E., Berridge, C. W., Foote, S. L., & Valentino, R. J. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90862-f · Cited by 106 · cited 1×
“Brain noradrenergic activity is closely associated with behavioral and physiological indices of arousal, such as locomotion, eye movements, EEG activity, heart rate, and overt behavioral activity (Rasmussen et al, 1986; Berridge and Foote, 1991; Page et al, 1993; Rosario and Abercrombie, 1999).”
BackgroundBarriers to seeking treatment for major depression
Blumenthal*, R., & Endicott, J. (1996) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1996)4:6<273::aid-da3>3.0.co;2-d · Cited by 106
Bonhomme, N., & Esposito, E. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199812000-00005 · Cited by 97 · cited 1×
“This later behavioral effect of paroxetine may not be due to serotonin exclusively, but to sequential or direct interactions between serotonin and noradrenergic or even dopaminergic systems (Willner, 1997; Bonhomme and Esposito, 1998; Bourin et al, 2001).”
BackgroundTreatment of Generalized Anxiety Disorder
(2013) · Cognitive Coping Therapy · doi:10.4324/9780203782668-12 · Cited by 96
Norepinephrine involvement in antidepressant action.
Frazer, A. (2000) · PubMed · Cited by 89
Self-citationJoyce, P. R., Mulder, R. T., Luty, S. E., McKenzie, J. M., & Rae, A. M. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00120.x · Cited by 80 · cited 1×
“Both Korstein et al (2000) and Joyce et al (2003) reported that men responded less well to SSRIs such as sertraline and fluoxetine than to TCAs.”
BackgroundJavors, M. A., Houston, J. P., Tekell, J. L., Brannan, S. K., & Frazer, A. (2000) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570000198x · Cited by 77 · cited 1×
“Plasma concentrations of drugs were measured by highperformance liquid chromatography exactly as described in Javors et al (2000).”
MethodSelf-citationBehavioural measurement and drug response characteristics of unipolar and bipolar depression
Katz, M. M., Robins, E., Croughan, J., Secunda, S., & Swann, A. (1982) · Psychological Medicine · doi:10.1017/s0033291700043257 · Cited by 71 · cited 2×
“These have been described previously (Katz et al, 1982, 1984, 1989).”
MethodSelf-citationSingle-unit and physiological analyses of brain norepinephrine function in behaving animals.
Jacobs, B. L., Abercrombie, E., Fornal, C., Levine, E., Morilak, D. A., & Stafford, I. (1991) · Progress in Brain Research · doi:10.1016/s0079-6123(08)63805-4 · Cited by 70 · cited 1×
“Tonic noradrenergic activity is closely related to the overall state of behavioral arousal, which may be conceptualized as the degree to which an organism is ‘engaged’ with or responsive to its external environment (Aston-Jones et al, 1991; Jacobs et al, 1991).”
BackgroundKatz, M. M., Secunda, S., Koslow, S. H., Maas, J. W., Berman, N., Casper, R., Kocsis, J., & Stokes, P. (1984) · Psychological Reports · doi:10.2466/pr0.1984.55.2.619 · Cited by 70 · cited 6×
“These have been described previously (Katz et al, 1982, 1984, 1989).”
BackgroundMethodInfluentialSelf-citationFrazer, A. (1997) · PubMed · Cited by 70
Self-citationRosario, L. A., & Abercrombie, E. D. (1999) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00040-4 · Cited by 68 · cited 1×
“Brain noradrenergic activity is closely associated with behavioral and physiological indices of arousal, such as locomotion, eye movements, EEG activity, heart rate, and overt behavioral activity (Rasmussen et al, 1986; Berridge and Foote, 1991; Page et al, 1993; Rosario and Abercrombie, 1999).”
BackgroundKatz, M. M., Koslow, S. H., & Frazer, A. (1996) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1996)4:6<257::aid-da1>3.0.co;2-9 · Cited by 67 · cited 1×
“Recent reviews of relevant research on the issue of the onset of action of AD drugs (Stassen et al, 1993; Katz et al, 1996/ 1997; Gelenberg and Chesen, 2000) concluded that none of these studies, including ours, had fully met the requirements of a definitive study on response onset.”
BackgroundSelf-citationTollefson, G. D., & Holman, S. L. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199400940-00003 · Cited by 63 · cited 1×
“Large meta-analytic studies analyzing data post hoc from pharmaceutical trials additionally found evidence of early behavioral changes in the first 2 weeks of treatment (Dunbar and Fuell, 1992; Tollefson and Holman, 1994).”
BackgroundOnset of response in relation to outcome in depressed outpatients with placebo and imipramine
Khan, A., Cohen, S., Dager, S. R., Avery, D. H., & Dünner, D. L. (1989) · Journal of Affective Disorders · doi:10.1016/0165-0327(89)90021-9 · Cited by 53 · cited 2×
“…(eg Quitkin et al, 1984) or whether the behavioral effects begin to act sooner, within the first week, as originally observed (Kuhn, 1958; Kielholz and Poldinger, 1968; Angst, 1970), and as found in a number of subsequent clinical studies (Katz et al, 1987; Khan et al, 1989; Stassen et al, 1993).”
BackgroundResultDelayed onset of action of antidepressant drugs? Survey of recent results
Stassen, H. H., Angst, J., & Delini-Stula, A. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)89100-6 · Cited by 50 · cited 5×
“The results on the onset and timing of response agree generally with those found by Stassen et al (1993, 1997), in that significant improvement occurs as early as 13 days for most ADs.”
BackgroundMethodResultInfluentialVideo Methodology for Research in Psychopathology and Psychopharmacology: Rationale and Application
Katz, M. M. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760140056009 · Cited by 47 · cited 3×
“On the basis of that interview, the clinician completes the SADS-C ratings, the HAM-D (it is incorporated into the SADS-C interview), and the brief VIBES (25 mood and behavior items).”
MethodSelf-citationKatz, M. M., Maas, J. W., Frazer, A., Koslow, S. H., Bowden, C. L., Berman, N., Swann, A. C., & Stokes, P. E. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.38 · Cited by 40 · cited 1×
“The design allowed us to test hypotheses based on earlier findings (Katz et al, 1994) that early behavioral change to the SSRI, paroxetine, would be on anxiety, whereas those to the selective NRI, DMI, would be on motor activity and that such early improvement would be predictive of a positive…”
MethodSelf-citationDie Behandlung endogener Depressionen mit Psychopharmaka
Kielholz, P., & Pöldinger, W. (1968) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1105133 · Cited by 36 · cited 2×
“…action (eg Quitkin et al, 1984) or whether the behavioral effects begin to act sooner, within the first week, as originally observed (Kuhn, 1958; Kielholz and Poldinger, 1968; Angst, 1970), and as found in a number of subsequent clinical studies (Katz et al, 1987; Khan et al, 1989; Stassen et…”
BackgroundThe Anti-anxiety and Anti-agitation Effects of Paroxetine in Depressed Patients
Dunbar, G. C., & Fuell, D. (1992) · International Clinical Psychopharmacology · doi:10.1097/00004850-199206004-00014 · Cited by 33
Prediction of efficacy of antidepressant by 1-week test therapy in depression
Nagayama, H., Nagano, K., Ikezaki, A., & Tetsuo, T. (1991) · Journal of Affective Disorders · doi:10.1016/0165-0327(91)90102-x · Cited by 33 · cited 2×
“The lack of a placebo control group in several of the other prediction studies, for example, Nagayama et al (1991), also brought into question the etiology of these reported early clinical actions.”
ResultCoryell, W., Coppen, A., Zeigler, V. E., & Biggs, J. T. (1982) · Psychological Medicine · doi:10.1017/s0033291700043385 · Cited by 33 · cited 1×
“Findings from a number of other studies (Small et al, 1981; Coryell et al, 1982; Khan et al, 1989; Nagayama et al, 1991; Stassen et al, 1993; Boyer and Feighner, 1994) have also confirmed the positive role of early clinical actions in predicting treatment outcome.”
ResultThe Advantages of Paroxetine in Different Subgroups of Depression
Montgomery, S. (1992) · International Clinical Psychopharmacology · doi:10.1097/00004850-199206004-00015 · Cited by 31 · cited 1×
“Clinical research reaffirms the association of the functioning of the serotonin system and impulsive, aggressive behavior (Coccaro et al, 1989), and also indicates a specific and strong association with anxiety (Dunbar and Fuell, 1992; Montgomery, 1992; Gorman, 2002).”
BackgroundTherapeutic advances: Paroxetine for the treatment of social anxiety disorder
Lydiard, R. B., & Bobes, J. (2000) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(2000)11:3<99::aid-da3>3.0.co;2-z · Cited by 22 · cited 1×
“The pattern is further supported by paroxetine’s use as an ‘anxiolytic’, now FDA approved for the treatment of a range of anxiety disorders (Dunbar and Fuell, 1992; Lydiard and Bobes, 2000; Pollack et al, 2001).”
BackgroundPsychopharmacology and the Etiology of Psychopathologic States: Are We Looking in the Right Way?
Katz, M. M., & Maas, J. W. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.16 · Cited by 21 · cited 2×
“…resolve the complex, clinical state of depression, it is useful to view the impact of the drugs on the three major severity dimensions of the disorder, that is, DM-MR, anxiety– agitation–somatization (‘arousal’), and hostility–interpersonal sensitivity (Katz et al, 1984; Katz and Maas, 1994).”
BackgroundSelf-citationSmall, J. G., Milstein, V., Kellams, J. J., & Small, I. F. (1981) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198111001-00012 · Cited by 19 · cited 1×
“Findings from a number of other studies (Small et al, 1981; Coryell et al, 1982; Khan et al, 1989; Nagayama et al, 1991; Stassen et al, 1993; Boyer and Feighner, 1994) have also confirmed the positive role of early clinical actions in predicting treatment outcome.”
ResultSerotonin in anxiety: evidence from animal models
Briley, M., & Chopin, P. (1991) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780192620118.003.0015 · Cited by 18 · cited 2×
“More specifically at the behavioral level, it has been associated with the regulation of impulsivity (Soubrié, 1986), aggression (Linnoila et al, 1983), and anxiety (Briley and Chopin, 1991).”
Background5-Hydroxytryptamine in Psychiatry
Pedigo, N. W. (1992) · Current Opinion in Cardiology · doi:10.1097/00001573-199202000-00031 · Cited by 13
Video Methodology in the Study of the Psychopathology and Treatment of Depression
Katz, M. M., Wetzler, S. E., Koslow, S. H., & Secunda, S. K. (1989) · Psychiatric Annals · doi:10.3928/0048-5713-19890701-10 · Cited by 11 · cited 1×
“These have been described previously (Katz et al, 1982, 1984, 1989).”
MethodSelf-citationClinical significance of early non‐response in depressed patients
Boyer, W. F., & Feighner, J. P. (1994) · Depression · doi:10.1002/depr.3050020104 · Cited by 9 · cited 1×
“Findings from a number of other studies (Small et al, 1981; Coryell et al, 1982; Khan et al, 1989; Nagayama et al, 1991; Stassen et al, 1993; Boyer and Feighner, 1994) have also confirmed the positive role of early clinical actions in predicting treatment outcome.”
Result
Research works printed but not linked: 3
- Guy W (1976). Early clinical drug evaluation program (ECDEU). In: Assessment Manual of Psychopharmacology. Department of Health, Education and Welfare: Rockville MD.
- Murphy DL, Pickar D, Alterman JS (1980). Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EJ, Sudilovsky A, Gershon S (eds) Quantitative Techniques for the Evaluation of the Behavior of Psychiatric Patients. Marcel-Decker: New York, 355–392.
- Spitzer RL, Williams JBW (1983). Instruction manual For the Structured Clinical Interview for DSM III (SCID), Revision. Biometrics Research Department, M.Y. State Psychiatric Institute: New York.
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“While preliminary data were suggestive (Dubini et al., 1997; Katz et al., 2004), an analysis of two RCTs of reboxetine against fluoxetine found no reproducible difference in degree of improvement of different symptoms (Nelson et al.”
ResultDopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
“Indeed, when the treatment is effective, it can take weeks to get a therapeutic effect (Katz et al., 2004).”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…strongly suggesting that a true drug response can be observed within the fi rst 14 days of treatment (Nierenberg et al. 2000; Szegedi et al. 2003; Katz et al. 2004; Posternak and Zimmerman 2005; Papakostas et al. 2006; Taylor et al. 2006; Stassen et al. 2007; Henkel et al. 2009; Hennings et…”
BackgroundMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Metadata
- Authors
- Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Dallas VA Medical Center (US)
- Harbor–UCLA Medical Center (US)
- Corresponding author
- Frazer, Alan
- ORCID
- Frazer, Alan
- Venue
- Neuropsychopharmacology
- Published
- 2003-11-19
- Volume
- 29
- Issue
- 3
- Pages
- 566-579
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2319982487
- Cited by
- 252
- References
- 72
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 7 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 8 · 2016: 14 · 2015: 13 · 2014: 10 · 2013: 20 · 2012: 7
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressant onset of action, depression, paroxetine, desipramine, selective serotonin reuptake inhibitors, noradrenergic reuptake inhibitors, placebo response, motor retardation, depressive mood, anxiety, treatment response prediction
- MeSH terms
- Adult, Affect, Aged, Analysis of Variance, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Desipramine, Double-Blind Method, Female, Humans, Male, Middle Aged, Motor Activity, Time Factors, Placebo Effect, Chi-Square Distribution, Logistic Models, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.